Israeli biotech company develops new treatment for inflammatory diseases and cancer

November 27, 2023 , ,
The therapy developed by Amoprhical has the ability to stimulate healing in tissue damaged during treatment. Photo: Chokniti Khongchum/Pexels.The therapy developed by Amoprhical has the ability to stimulate healing in tissue damaged during treatment. Photo: Chokniti Khongchum/Pexels.

Amorphical is a biotechnology company established in Israel, more specifically in Nes Ziona, in 2004. It is a pioneering organization in the development and manufacture of natural-based medicines aimed at improving the absorption and management of calcium, in addition to balancing the level of acidity (pH) of the body derived from various biomedical conditions.

The Israeli company has an innovative approach to the treatment of various chronic inflammatory diseases and cancer that is mineral-based. This is an innovative technology that enables the production of amorphous calcium carbonate, allowing the body to quickly and efficiently absorb essential minerals.

This treatment has application both in inflammatory diseases, such as Crohn's disease, but also for arthritis and breast, prostate and colon cancer. Mineral therapy has also proven to be highly effective in the treatment of COVID-19.

According to its clinical trials, the treatment developed by Amorphical stimulates healing in tissue damaged during treatment, thanks to the unique dissolving properties of the mineral.

Calcium carbonate neutralizes the acidity in the affected tissue, creating a neutral environment that prevents inflammation and therefore inhibits the growth of cancer cells, since they need an acidic environment to reproduce quickly.

Share
2 thoughts on “An Israeli biotechnology company develops a new treatment for inflammatory diseases and cancer”

Leave your comment

Your email address will not be published. Required fields are marked with *

This site uses Akismet to reduce spam. Learn how your comment data is processed.